Summary:
Enada NADH, otherwise known as nicotinimide adenine dinucleotide, has proven itself to be remarkably useful in treating degenerative medical disorders. Clinical trials in Europe found that patients suffering from Alzheimer's disease showed cognitive improvement after treatment with Enada NADH.

Alzheimer's disease is characterized by increasing memory loss and dementia as a result of the degeneration of brain cells. Although there are drugs (tacrine) which can temporarily slow the onset of Alzheimer's disease, there is not yet a cure. Patients who take tacrine can take Enada NADH as well without incurring any negative interactions.

NADH has the ability to benefit patients suffering from Alzheimer's disease by replenishing energy in fatigued brain cells, increasing the functionings of brain neurotransmitters, repairing cellular DNA, and stimulating the immune system.

The director in charge of the trials testing NADH as a treatment of Alzheimer's disease, Dr. Stanley Cohan, says: Currently, proven treatments and therapies for people with Alzheimer's disease are inadequate. NADH is a naturally-occurring compound (a coenzyme) with few side effects that has shown promise in Europe and is in preliminary trials with Alzheimer's disease patients.